P002: Targeted Oncology Therapy

P002 is an advanced biosimilar designed to inhibit the growth of blood vessels that supply tumors, offering a vital treatment option for a range of cancers. By disrupting the tumor’s blood supply, P002 enhances treatment efficacy in patients with late-stage cancers. Engineered to deliver quality at a reduced cost, P002 is positioned to become a critical therapy in oncology care. Anticipated regulatory approval is set for 2026, with global distribution plans underway.